Dr. Wang joined in BeiGene’s early days, in 2011. Currently the Global Head of R&D, his previous roles in the company have included heading the Discover Biomarkers and In VivoPharmacology groups and supporting clinical programs with the study of clinical biomarkers and translational research. He was appointed head of China Development in 2016, responsible for clinical development in the Asia-Pacific region.

Prior to joining BeiGene, Dr. Wang was the director of research at Joyant Pharmaceuticals, a biotech company based in Dallas, Texas.

Dr. Wang received his B.S. in 1996 from Fudan University and Ph.D. in 2001 from University of Texas Health Science Center at San Antonio. He completed his post-doc training with Dr. Xiaodong Wang at Howard Hughes Medical Institute.